Загрузка...
Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
BACKGROUND: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documented in the...
Сохранить в:
| Опубликовано в: : | Clin Transl Allergy |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5870812/ https://ncbi.nlm.nih.gov/pubmed/29599966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-018-0195-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|